Novavax (DE:NVV1)
FRANKFURT:NVV1
NVV1 Stock Chart & Stats
€7.10
-€1.01(-9.65%)
At close: 4:00 PM EST
€7.10
-€1.01(-9.65%)
Day’s Range― - ―
52-Week Range€4.82 - €10.03
Previous CloseN/A
Volume7.16K
Average Volume (3M)3.54K
Market Cap
€1.18B
Enterprise Value€1.40B
Total Cash (Recent Filing)€735.08M
Total Debt (Recent Filing)€248.81M
Price to Earnings (P/E)2.5
Beta2.29
Next Earnings
May 13, 2026EPS Estimate
-0.2Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.09
Shares Outstanding162,935,940
10 Day Avg. Volume1,202
30 Day Avg. Volume3,544
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)-8.52
Price to Sales (P/S)0.97
P/FCF Ratio-4.35
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€11.51Price Target Upside62.18% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering7
EPS Forecast (FY)-0.34
Revenue Forecast (FY)€339.69M
Bulls Say, Bears Say
Bulls Say
Business Model Shift And Pipeline FocusA strategic shift toward a high-margin licensing model alongside an internal focus on RSV and shingles increases the potential for long-term revenue from partnerships and targeted vaccine launches.
Expense Reductions And FinancingSustained reductions in operating expenses combined with access to non-dilutive financing support a pathway to adjusted profitability while limiting shareholder dilution.
Pfizer Licensing ValidationA licensing agreement with a major pharmaceutical partner validates Matrix-M technology and creates a pathway to upfront payments, milestones, and tiered royalties that can generate recurring licensing revenue without full commercialization risk.
Bears Say
Clinical Development Timing RiskUncertainty about how quickly Matrix-M collaborations will progress into clinical-stage trials limits the near-term likelihood of milestone payments and reduces short-term value realization.
Market Demand And Competitive UncertaintyUnclear future demand for COVID vaccines and doubts about partners' ability to capture meaningful market share introduce headline risk and weaken visibility into near-term revenue prospects.
Scientific Risk In Bacterial Vaccine ProgramsPursuing vaccines against bacterial pathogens such as C. difficile carries elevated scientific and development risk, making successful commercialization and related revenue less certain.
Novavax News
NVV1 FAQ
What was Novavax’s price range in the past 12 months?
Novavax lowest stock price was €4.82 and its highest was €10.03 in the past 12 months.
What is Novavax’s market cap?
Novavax’s market cap is €1.18B.
When is Novavax’s upcoming earnings report date?
Novavax’s upcoming earnings report date is May 13, 2026 which is in 33 days.
How were Novavax’s earnings last quarter?
Novavax released its earnings results on Feb 26, 2026. The company reported €0.094 earnings per share for the quarter, beating the consensus estimate of -€0.416 by €0.51.
Is Novavax overvalued?
According to Wall Street analysts Novavax’s price is currently Undervalued.
Does Novavax pay dividends?
Novavax does not currently pay dividends.
What is Novavax’s EPS estimate?
Novavax’s EPS estimate is -0.2.
How many shares outstanding does Novavax have?
Novavax has 162,935,940 shares outstanding.
What happened to Novavax’s price movement after its last earnings report?
Novavax reported an EPS of €0.094 in its last earnings report, beating expectations of -€0.416. Following the earnings report the stock price went up 16.271%.
Which hedge fund is a major shareholder of Novavax?
Currently, no hedge funds are holding shares in DE:NVV1
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Novavax Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€11.51 (62.18% Upside)
€11.51 (62.18% Upside)
Blogger Sentiment
Bullish
DE:NVV1 Sentiment 75%
Sector Average 69%
Sector Average 69%
News Sentiment
Bearish
Bullish news 33%
Bearish news 67%
Bearish news 67%
Technicals
SMA
Positive
20 days / 200 days
Momentum
33.43%
12-Months-Change
Fundamentals
Return on Equity
-546.21%
Trailing 12-Months
Asset Growth
-26.20%
Trailing 12-Months
Company Description
Novavax
Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; NanoFlu, a nanoparticle seasonal quadrivalent influenza vaccine candidate that is in Phase 3 clinical trial; and ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine candidate. It is also developing RSV F vaccine that is in Phase II clinical trial for older adults (60 years and older), as well as that is in Phase I clinical trial for pediatrics. It has a collaboration agreement with Takeda Pharmaceutical Company Limited for the development, manufacturing, and commercialization of NVX-CoV2373, a COVID-19 vaccine candidate. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.
NVV1 Company Deck
NVV1 Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call emphasized substantial progress: robust revenue growth (driven partly by noncash APA resolution), profitability in both Q4 and full‑year 2025, strong cash and credit resources with a runway into 2028, meaningful cost reductions, and accelerating partnership momentum (notably Pfizer and Sanofi) that together present a clear path to lower run‑rate costs and potential future milestone and royalty upside. Key risks highlighted include reliance on partner execution for meaningful future revenue, certain milestone timing uncertainties (tech transfer and Phase III milestones with Sanofi), front‑loaded partner‑related spending in 2026, and broader regulatory uncertainties that could affect product uptake. Overall, the positives (growth, profitability, cash runway, partnerships, and disciplined cost cuts) substantially outweigh the listed risks, though future value remains contingent on partner success and regulatory developments.View all DE:NVV1 earnings summariesNVV1 Stock 12 Month Forecast
Average Price Target
€11.51
▲(62.18% Upside)
Technical Analysis
Vir Biotechnology
―
Oric Pharmaceuticals
―
―
AbCellera Biologics
―
Sana Biotechnology
―
Options Prices
Currently, No data available
---